DiscoverCME in Minutes: Education in Oncology & Hematology
CME in Minutes: Education in Oncology & Hematology
Claim Ownership

CME in Minutes: Education in Oncology & Hematology

Author: Answers in CME

Subscribed: 20Played: 374
Share
© 2022

Description

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
179 Episodes
Reverse
Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies

Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies

2025-12-1001:13:41

Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participants should be better able to: Identify the rationale for anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM); Evaluate the clinical implications of evidence on anti-CD38 monoclonal antibody–containing quadruplet therapies in patients with NDMM; and Review strategies to optimize anti-CD38 monoclonal antibody–containing quadruplet therapies, including in the community setting.
Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy

Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy

2025-12-0901:03:38

Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.
Prof. Solange Peters, MD, PhD / David Harpole, MD - Perioperative Immunotherapy: A Multidisciplinary Blueprint for Optimizing Outcomes in Resectable NSCLC

Prof. Solange Peters, MD, PhD / David Harpole, MD - Perioperative Immunotherapy: A Multidisciplinary Blueprint for Optimizing Outcomes in Resectable NSCLC

2025-12-0831:57

Please visit answersincme.com/860/97150451-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss case-based strategies for integrating perioperative immunotherapy in resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC.
Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care

Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care

2025-12-0501:00:55

Please visit answersincme.com/860/IME-69386-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in NSCLC discuss how to harness targeted ADCs with practical, case-based insights to personalize care and improve outcomes in advanced lung cancer. Upon completion of this activity, participants should be better able to: Interpret the latest clinical trial data for approved and emerging antibody-drug conjugates (ADCs) in NSCLC; Recognize biomarker-driven strategies to guide treatment management in patients with NSCLC; and Apply evidence-based strategies for the individualized management of patients with NSCLC receiving ADC therapy.
Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach

Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach

2025-12-0217:07

Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.
Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

2025-12-0101:02:39

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.
Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront

Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront

2025-11-2812:26

Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.
Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

2025-11-2521:11

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.
Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

2025-11-2430:39

Please visit answersincme.com/860/97851223-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the latest advances in the treatment of small-cell lung cancer (SCLC), including both extensive-stage and limited-stage disease. Upon completion of this activity, participants should be better able to: Identify clinical factors that drive treatment decision-making for patients with SCLC; and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
Christine Brezden-Masley, MD, PhD, FRCPC - Reducing Risk of Recurrence in HR+, HER2-, High-Risk Early Breast Cancer: Optimizing Risk Stratification and Use of Adjuvant CDK4/6 Inhibitors

Christine Brezden-Masley, MD, PhD, FRCPC - Reducing Risk of Recurrence in HR+, HER2-, High-Risk Early Breast Cancer: Optimizing Risk Stratification and Use of Adjuvant CDK4/6 Inhibitors

2025-11-2114:40

Please visit answersincme.com/XRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses how to optimize the use of adjuvant CDK4/6 inhibitors for managing patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. A patient also shares their experience with adjuvant CDK4/6 inhibitor therapy. Upon completion of this activity, participants should be better able to: Identify patients with hormone receptor–positive, HER2-negative, early breast cancer who are at a high risk of recurrence; Review current guidelines and evidence informing the use of adjuvant CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer; and Outline patient-centered strategies to optimize outcomes with adjuvant CDK4/6 inhibitors in hormone receptor–positive, HER2-negative, high-risk early breast cancer.
Komal Jhaveri, MD, FACP, FASCO - From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer

Komal Jhaveri, MD, FACP, FASCO - From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer

2025-11-2021:38

Please visit answersincme.com/ZWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer; Review the clinical profiles of TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer; and Apply guideline-concordant, evidence-based strategies to incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer.
Arielle Elkrief, MD / Normand Canty - Cases in Metastatic NSCLC: Optimizing Long-term Outcomes With Frontline Immunotherapy-Based Regimens

Arielle Elkrief, MD / Normand Canty - Cases in Metastatic NSCLC: Optimizing Long-term Outcomes With Frontline Immunotherapy-Based Regimens

2025-11-1918:09

Please visit answersincme.com/JXV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metastatic non–small-cell lung cancer discusses how to optimize frontline immunotherapy-based regimens for long-term outcomes. Upon completion of this activity, participants should be better able to: Identify patients with metastatic NSCLC who may benefit from first-line immunotherapy-based regimens; Evaluate the long-term evidence on first-line immunotherapy-based regimens for the treatment of patients with metastatic NSCLC; and Outline evidence-based, patient-centered strategies to ensure optimal use of first-line immunotherapy-based regimens, from initiation to follow-up care after discontinuation, in patients with metastatic NSCLC.
Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

2025-11-1817:08

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.
Alison Sehgal, MD - The Case for CAR T-Cell Therapy in Second-Line R/R LBCL: A Framework for Long-Term Success

Alison Sehgal, MD - The Case for CAR T-Cell Therapy in Second-Line R/R LBCL: A Framework for Long-Term Success

2025-11-0618:46

Please visit answersincme.com/BJV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses CD19-directed CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma. Upon completion of this activity, participants should be better able to: Review the rationale for CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; Discuss the clinical profiles of available CD19-directed CAR T-cell therapies for patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; and Outline patient-centered strategies for optimizing treatment with CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy.
Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC

Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC

2025-11-0319:09

Please visit answersincme.com/SAM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the importance of molecular testing in the treatment of advanced squamous NSCLC with immunotherapy. Upon completion of this activity, participants should be better able to: Assess the role of molecular testing in guiding first-line treatment selection for patients with advanced squamous non–small-cell lung cancer (NSCLC); Review the practical implications of the clinical evidence evaluating preferred combination immunotherapy regimens for the initial management of advanced squamous NSCLC; and Outline clinical, evidence-based strategies to optimize the provision of long-term care for patients with advanced squamous NSCLC receiving combination immunotherapy regimens.
Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care

Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care

2025-10-3031:21

Please visit answersincme.com/860/97851223-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the growing importance of immunotherapy in the management of limited-stage small-cell lung cancer (LS-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Identify clinical factors that drive treatment decision-making for patients with SCLC.
Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs

Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs

2025-10-2801:17:43

Please visit answersincme.com/860/98336099-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss use of antibody-drug conjugates (ADCs) for patients with hormone-receptor (HR)–positive, HER2-low and -ultralow metastatic breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of HER2-low and ultralow status in patients with metastatic breast cancer (mBC); Integrate testing strategies for HER2-low and ultralow mBC; Evaluate the clinical data for antibody drug conjugates (ADCs) in HER2-low and ultralow mBC; and Propose practical strategies to enhance the current and future use of ADCs in HER2-low and -ultralow mBC.
Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

2025-10-2816:10

Please visit answersincme.com/ZMN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses first-line treatment of advanced EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Review current guideline recommendations for the first-line treatment of advanced EGFR-mutated NSCLC; Describe the clinical implications of the latest evidence on first-line therapeutic strategies for advanced EGFR-mutated NSCLC; and Outline evidence-based strategies to personalize first-line therapeutic selection for patients with advanced EGFR-mutated NSCLC.
Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

2025-10-1501:05:40

Please visit answersincme.com/860/240201301-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss how the latest evidence on frontline immunotherapy-based regimens can be integrated into practice to optimize outcomes for patients with advanced NSCLC. Upon completion of this activity, participants should be better able to: Review the latest data on frontline immunotherapy-based regimens for the treatment of advanced NSCLC; Identify patient-, disease-, and drug-related factors that may inform the frontline use of immunotherapy-based regimens for advanced NSCLC; and Outline evidence-based, multidisciplinary strategies to optimize long-term patient outcomes with frontline immunotherapy-based regimens in advanced NSCLC.
Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

2025-10-0321:30

Please visit answersincme.com/MPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myelodysplastic syndromes discusses strategies for the management of FLT3-mutated acute myeloid leukemia. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML); Recognize the clinical significance of the evidence for approved FLT3 inhibitors in the first-line treatment of newly diagnosed, FLT3-mutated AML; Formulate strategies to maximize the impact of FLT3 inhibitors in the management of patients with newly-diagnosed, FLT3-mutated AML.
loading
Comments 
loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States